Mark Curtis
Mark is a Business Development Analyst at the Centre for Commercialization of Regenerative Medicine (CCRM), where he collaborates with the team to help evaluate the commercial potential of regenerative medicine and cell therapy technologies. He began his career at Princess Margaret Hospital studying cellular reprogramming of human skin cells. Following this project, he left the laboratory and took on a role with Bloom Burton & Co., a healthcare-focused investment dealer. While there he supported the advisory team in carrying out scientific diligence on early-stage biotechnology companies. Prior to joining CCRM he was a consultant to Stem Cell Therapeutics, a Toronto-based biotechnology company focused on developing therapeutics targeting cancer stem cells. Mark received a Master’s degree from the University of New South Wales in Sydney, where he studied the directed differentiation of embryonic stem cells, and a Bachelor’s degree in Biology, from Queen’s University. Follow Mark on Twitter @markallencurtis
Posts by: Mark
Update from the Clinic: February
. Welcome to your update from the clinic for the month of February! OncoMed is the leader in news this month with various Phase 1b trials for its cancer stem cell-targeting fusion protein. Immunocellular Therapeutics and StemCells Inc. file orphan drug designations with the European Medicines Agency and FDA for their respective cell therapies. Read […]
Regenerative Medicine Deal Review: January
. Welcome to your Regenerative Medicine Deal Review for the month of January! There was lots of flow in January, including yet another research collaboration from Cellular Dynamics International – this time with the Nestle Institute of Health Sciences to use the company’s iCell® and MyCell® products for research into human nutrition. Aastrom entered into […]
Update from the Clinic: January
. Welcome to your Update from the Clinic for the month of January! We start the year off with the German health authority approving Pluristem’s next generation GMP cell manufacturing facility. Neuralstem successfully, and safely, transplants NSI-556 cells directly into the brain of its first patient in a Phase 1/2 study. Meanwhile, OncoMed and StemCells […]
Regenerative Medicine Deal Review: December
. Welcome to your Regenerative Medicine Deal Review for the month of December. Toronto-based Stem Cell Therapeutics successfully executed on a financing of $33 million, while Pluristem announces it is moving forward on a licensing agreement with Korea-based CHA. Cellular Dynamics International is back in the news this month with another collaboration, this time to […]
Update from the Clinic: December
. Welcome to your Update from the Clinic for the month of December. Athersys and NeoStem both confirm completion of enrollment for phase 2 studies while bluebird bio announces the first patient transplanted in its phase 1/2 study of HGB-205 in patients with beta-thalassemia and sickle cell anemia. Read on to find out more. Cleveland-based […]
Comments